Assess whether regulatory approval is a timing risk or a deal risk (c7f6f7)

SITUATION The working file is carve-out stranded-cost model after a CIM that omitted a material litigation. IP diligence counsel's financial counterpart in a cross-border deal with earnout-heavy structure has to name Regulatory approval is a timing risk or A deal risk for this M&A Due Diligence People and Contracts file.

DECISION IP diligence counsel's financial counterpart in a cross-border deal with earnout-heavy structure must choose Regulatory approval is a timing risk / A deal risk using carve-out stranded-cost model after a CIM that omitted a material litigation.

HYPOTHESES TO TEST 1. IP diligence counsel's financial counterpart can defend Regulatory approval is a timing risk from carve-out stranded-cost model after a CIM that omitted a material litigation in a M&A Due Diligence challenge. 2. IP diligence counsel's financial counterpart cannot defend Regulatory approval is a timing risk from carve-out stranded-cost model; A deal risk is what the extract actually supports after a CIM that omitted a material litigation. 3. A CIM that omitted a material litigation never reached the population in carve-out stranded-cost model — reopen intake, do not close regulatory approval is a. 4. Two facts in carve-out stranded-cost model after a CIM that omitted a material litigation conflict for IP diligence counsel's financial counterpart; hold this People and Contracts file.

ANALYSIS REQUIRED 1. Test whether a CIM that omitted a material litigation is a diligence gap, a price chip, or a walk-away. 2. Separate a one-off add-back from a recurring earnings issue in carve-out stranded-cost model. 3. Map reps, earnout mechanics, and integration risk a cross-border deal with earnout-heavy structure would inherit. 4. For this M&A Due Diligence People and Contracts file, read carve-out stranded-cost model against a CIM that omitted a material litigation and write the one fact that would move regulatory approval is a for IP diligence counsel's financial counterpart.

RECOMMENDATION Choose Regulatory approval is a timing risk / A deal risk on this M&A Due Diligence / People and Contracts packet (carve-out stranded-cost model after a CIM that omitted a material litigation). Lead with the M&A Due Diligence option carve-out stranded-cost model can support after a CIM that omitted a material litigation, then the two facts that force it, then the Monday action for IP diligence counsel's financial counterpart in a cross-border deal with earnout-heavy structure.

COMMAND RETURNS - Bottom-line M&A Due Diligence option on regulatory approval is a, then the evidence in carve-out stranded-cost model, then the action for IP diligence counsel's financial counterpart - Hypothesis scorecard against carve-out stranded-cost model: supported / rejected / untestable - People and Contracts finding in carve-out stranded-cost model that a second reviewer can re-perform - Missing page in carve-out stranded-cost model after a CIM that omitted a material litigation, if any